Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.31 |
| ▸ | WNT3A | P56704 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852362 | 0.93 | PTGS2 (0.42) | PTGS2PTGS1CTNNB1WNT3A | |
| SCHEMBL4861134 | 0.89 | PTGS2 (0.47) | PTGS2PTGS1PARP1CTNNB1WNT3A | |
| SCHEMBL4860602 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4857154 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1ALOX5 | |
| SCHEMBL5308756 | 0.84 | PTGS2 (0.47) | PTGS2PTGS1CTNNB1WNT3AALOX5 | |
| SCHEMBL4856564 | 0.83 | PTGS2 (0.45) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4860657 | 0.82 | PTGS2 (0.41) | PTGS2PTGS1CTNNB1WNT3A | |
| SCHEMBL5312945 | 0.81 | PTGS2 (0.48) | PTGS2PTGS1PARP1CTNNB1WNT3A | |
| SCHEMBL4853042 | 0.81 | PTGS2 (0.35) | PTGS2PTGS1ALOX5 | |
| SCHEMBL5307876 | 0.79 | PTGS2 (0.45) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| CN-1589153-A | Prevention or treatment of urinary disorders | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-03-02 | — | — | CN | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | PTGS2 610/4885PTGS1 211/4885PARP1 2804/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | PTGS2 610/4885PTGS1 211/4885PARP1 2804/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | PTGS2 474/4885PTGS1 417/4885PARP1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.